• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck strategically shedding compounds

Merck strategically shedding compounds

July 7, 2011
CenterWatch Staff

Almost as soon as the Merck and Schering-Plough pipelines were combined in late 2009, Merck had to go through all of its compounds and decide which to shed, according to Chemical & Engineering News.

Though Merck has not specified a number for how many programs it is cutting overall, the pipeline reorganization is said to be substantial. In an interview with Meeta Chatterjee, Merck & Co.’s head of global outlicensing and asset management, she told the publication the first step in the process was charging every therapeutic franchise head with prioritizing their portfolios. While some companies, such as GlaxoSmithKline and Pfizer, have cut entire therapeutic areas, Merck chose to weed out programs from across its entire organization, she said.

The end result was a long list of molecules across all phases of development, and even some at the lead optimization stage, suddenly up for grabs. The list included some that, due to clauses in partnering agreements, had to be returned to a biotech company, others that would be sold outright, and some assets Merck hoped to keep ties to through a partnership that would include an option to buy back the program down the road after some of the development risk had been removed. Lastly, a handful of compounds were simply shelved because they showed signs of toxicity in early studies.

“Merck did some out-licensing in the past, but there was never a dedicated group, and the number of out-licensing deals were nowhere near what we were being asked to do,” Chatterjee said.

And given the sensitive nature of pharma research, finding partners is not so simple. “It’s almost reverse competitive intelligence,” she said.

Once Merck said it was reevaluating its pipeline, a slew of companies and venture capital firms came forward to express interest in assets, said Chatterjee. After the team put together full data packages on every program on the chopping block, they filtered through the requests and tried to find the right matches. In fewer cases, her team has sought to identify a partner that might be interested in a program.

Since completing the data packages on the compounds in December, Chatterjee’s group has done a few small deals, and hopes to complete a few more this year.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing